JP6728355B2 - 腫瘍細胞においてｗｎｔシグナル伝達に拮抗する二重パラトピックポリペプチド - Google Patents

腫瘍細胞においてｗｎｔシグナル伝達に拮抗する二重パラトピックポリペプチド Download PDF

Info

Publication number
JP6728355B2
JP6728355B2 JP2018528327A JP2018528327A JP6728355B2 JP 6728355 B2 JP6728355 B2 JP 6728355B2 JP 2018528327 A JP2018528327 A JP 2018528327A JP 2018528327 A JP2018528327 A JP 2018528327A JP 6728355 B2 JP6728355 B2 JP 6728355B2
Authority
JP
Japan
Prior art keywords
seq
single variable
immunoglobulin single
lrp6
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018528327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019506841A (ja
JP2019506841A5 (enExample
Inventor
ヴィットリア ツィンツァッラ
ヴィットリア ツィンツァッラ
クラウス ペーター キュンケレ
クラウス ペーター キュンケレ
マリー アンジュ ブイス
マリー アンジュ ブイス
カレン クロミー
カレン クロミー
ステファニー スターレンス
ステファニー スターレンス
ベアトリース ストリュブ
ベアトリース ストリュブ
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング, ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2019506841A publication Critical patent/JP2019506841A/ja
Publication of JP2019506841A5 publication Critical patent/JP2019506841A5/ja
Application granted granted Critical
Publication of JP6728355B2 publication Critical patent/JP6728355B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018528327A 2015-12-04 2016-12-02 腫瘍細胞においてｗｎｔシグナル伝達に拮抗する二重パラトピックポリペプチド Active JP6728355B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15197999.4 2015-12-04
EP15197999 2015-12-04
PCT/EP2016/079575 WO2017093478A1 (en) 2015-12-04 2016-12-02 Biparatopic polypeptides antagonizing wnt signaling in tumor cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020113792A Division JP2020178701A (ja) 2015-12-04 2020-07-01 腫瘍細胞においてｗｎｔシグナル伝達に拮抗する二重パラトピックポリペプチド

Publications (3)

Publication Number Publication Date
JP2019506841A JP2019506841A (ja) 2019-03-14
JP2019506841A5 JP2019506841A5 (enExample) 2019-04-25
JP6728355B2 true JP6728355B2 (ja) 2020-07-22

Family

ID=54782606

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018528327A Active JP6728355B2 (ja) 2015-12-04 2016-12-02 腫瘍細胞においてｗｎｔシグナル伝達に拮抗する二重パラトピックポリペプチド
JP2020113792A Withdrawn JP2020178701A (ja) 2015-12-04 2020-07-01 腫瘍細胞においてｗｎｔシグナル伝達に拮抗する二重パラトピックポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020113792A Withdrawn JP2020178701A (ja) 2015-12-04 2020-07-01 腫瘍細胞においてｗｎｔシグナル伝達に拮抗する二重パラトピックポリペプチド

Country Status (34)

Country Link
US (2) US10597449B2 (enExample)
EP (2) EP3383425B1 (enExample)
JP (2) JP6728355B2 (enExample)
KR (1) KR102802241B1 (enExample)
CN (1) CN108289943B (enExample)
AR (1) AR106949A1 (enExample)
AU (1) AU2016363787B2 (enExample)
BR (1) BR112018010537A2 (enExample)
CA (1) CA3006235A1 (enExample)
CL (1) CL2018001384A1 (enExample)
CO (1) CO2018005680A2 (enExample)
CY (1) CY1123454T1 (enExample)
DK (1) DK3383425T3 (enExample)
EA (1) EA201891331A1 (enExample)
ES (1) ES2821099T3 (enExample)
HR (1) HRP20201528T1 (enExample)
HU (1) HUE051777T2 (enExample)
IL (1) IL259119B (enExample)
LT (1) LT3383425T (enExample)
MA (2) MA43368B1 (enExample)
MX (1) MX380414B (enExample)
MY (1) MY200933A (enExample)
NZ (1) NZ742037A (enExample)
PE (1) PE20181515A1 (enExample)
PH (1) PH12018501155B1 (enExample)
PL (1) PL3383425T3 (enExample)
PT (1) PT3383425T (enExample)
RS (1) RS60823B1 (enExample)
SA (1) SA518391728B1 (enExample)
SG (1) SG11201804510PA (enExample)
SI (1) SI3383425T1 (enExample)
TW (1) TWI734719B (enExample)
UA (1) UA122079C2 (enExample)
WO (1) WO2017093478A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020178701A (ja) * 2015-12-04 2020-11-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 腫瘍細胞においてｗｎｔシグナル伝達に拮抗する二重パラトピックポリペプチド

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6397335B2 (ja) 2012-02-28 2018-09-26 ノバルティス アーゲー ＲＮＦ４３変異ステータスを利用したＷｎｔシグナル伝達阻害剤の投与のためのがん患者選択法
MA43260A (fr) 2015-11-18 2018-09-26 Merck Sharp & Dohme Liants pd1 et/ou lag3
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
MA48760A (fr) * 2017-05-31 2020-04-08 Boehringer Ingelheim Int Polypeptides ayant un effet antagoniste sur la signalisation wnt dans des cellules tumorales
JP2020530454A (ja) 2017-08-07 2020-10-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 安全な細胞治療薬を生成するためのプラットフォーム
CN112040970A (zh) * 2017-11-29 2020-12-04 得克萨斯大学体系董事会 用于癌症疗法的组合物和方法
AU2018393073B2 (en) 2017-12-19 2025-09-18 Surrozen Operating, Inc. Wnt surrogate molecules and uses thereof
AU2019297522A1 (en) * 2018-07-05 2021-01-28 Surrozen Operating, Inc. Multi-specific Wnt surrogate molecules and uses thereof
WO2020080941A1 (en) * 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
AU2020250810A1 (en) * 2019-03-29 2021-09-02 Boehringer Ingelheim International Gmbh Anticancer combination therapy
CN113646048A (zh) 2019-03-29 2021-11-12 勃林格殷格翰国际有限公司 抗癌组合疗法
CA3139061A1 (en) 2019-05-04 2020-11-12 Inhibrx, Inc. Cd123-binding polypeptides and uses thereof
WO2020227481A1 (en) * 2019-05-08 2020-11-12 Bluebird Bio, Inc. Cd123 targeted immunotherapies
AU2020331424A1 (en) * 2019-08-14 2022-03-31 Antlera Therapeutics Inc. Antibodies that bind to LRP6 proteins and methods of use
CA3147827A1 (en) * 2019-08-14 2021-02-18 Modmab Therapeutics Inc. Antibodies that bind to lrp5 proteins and methods of use
AU2020355027A1 (en) 2019-09-23 2022-04-21 Twist Bioscience Corporation Antibodies that bind CD3 Epsilon
CN112794914B (zh) * 2019-11-14 2022-09-16 深圳华大生命科学研究院 一种基于噬菌体展示技术开发的alk纳米抗体及其应用
WO2021163490A1 (en) * 2020-02-14 2021-08-19 University Of Washington Targeted depletion of bacteria from mixed populations through programmable cell-cell adhesion
US12258406B2 (en) 2021-03-24 2025-03-25 Twist Bioscience Corporation Antibodies that bind CD3 Epsilon
EP4372006A4 (en) * 2021-07-16 2025-10-08 Brightpath Biotherapeutics Co Ltd ANTIBODY OR ANTIBODY DERIVATIVE TO TIM-3 ANTIGEN, AND USE THEREOF
CN120835898A (zh) * 2023-01-05 2025-10-24 哈珀恩治疗公司 用于治疗癌症的trop2靶向三特异性蛋白
CN116375851B (zh) * 2023-03-03 2024-03-22 中国农业科学院兰州兽医研究所 一种抗禽流感病毒np蛋白的纳米抗体及其制备方法与应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE452975T1 (de) 1992-08-21 2010-01-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
US6528054B1 (en) * 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
EP1558646A2 (en) 2002-11-08 2005-08-03 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses thereof
BRPI0518151A2 (pt) 2004-10-13 2009-06-16 Ablynx Nv polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
US7563619B2 (en) * 2006-05-30 2009-07-21 Van Andel Research Institute Mammary stem cell marker
CN102537051B (zh) 2006-06-08 2014-11-26 日本精工株式会社 具有密封圈的冲压外圈滚针轴承及其制造方法
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
CN100428934C (zh) 2006-09-07 2008-10-29 中国人民解放军第二军医大学 香豆素类化合物在制备诱导神经干细胞定向分化药物中的应用
CA2663042A1 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
EP2097449A1 (en) 2006-12-05 2009-09-09 Ablynx N.V. Peptides capable of binding to serum proteins
EP3305324A1 (en) 2007-11-02 2018-04-11 Novartis AG Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6)
AU2009221106A1 (en) 2008-03-05 2009-09-11 Ablynx Nv Novel antigen binding dimer-complexes, methods of making and uses thereof
JP2011516603A (ja) 2008-04-17 2011-05-26 アブリンクス エン．ヴェー． 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド
US8661423B2 (en) 2009-05-01 2014-02-25 Telcordia Technologies, Inc. Automated determination of quasi-identifiers using program analysis
US8276148B2 (en) 2009-12-04 2012-09-25 International Business Machines Corporation Continuous optimization of archive management scheduling by use of integrated content-resource analytic model
EP4219545A1 (en) 2009-12-23 2023-08-02 Novartis AG Method for decreasing immunogenicity
CA2788993A1 (en) 2010-02-05 2011-08-11 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
EA201201227A1 (ru) 2010-03-03 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Бипаратопные а-бета-связывающие полипептиды
EP2550295A1 (en) * 2010-03-24 2013-01-30 F. Hoffmann-La Roche AG Anti-lrp6 antibodies
EP2566892B1 (en) 2010-05-06 2017-12-20 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
CA2798390A1 (en) * 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
SG189271A1 (en) * 2010-10-20 2013-05-31 Genentech Inc Methods and compositions for modulating the wnt pathway
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US8790650B2 (en) * 2011-04-28 2014-07-29 Vanderbilt University Methods of using an antibody to inhibit WNT-mediated cardiac remodeling
JP6258199B2 (ja) 2011-06-23 2018-01-10 アブリンクス エン．ヴェー． 免疫グロブリン単一可変ドメインを伴うアッセイにおける非特異的タンパク質干渉を予測、検出及び低減するための技術
UA118833C2 (uk) 2011-08-17 2019-03-25 Ґлаксо Ґруп Лімітед Одиничний варіабельний домен імуноглобуліну, який зв'язується з tnfr1
EP3290442A1 (en) 2011-11-04 2018-03-07 Novartis AG Low density lipoprotein-related protein 6 (lrp6) half-life extender constructs
JP5949270B2 (ja) 2012-07-24 2016-07-06 富士通株式会社 オーディオ復号装置、オーディオ復号方法、オーディオ復号用コンピュータプログラム
WO2014029752A1 (en) * 2012-08-22 2014-02-27 Glaxo Group Limited Anti lrp6 antibodies
UA122079C2 (uk) * 2015-12-04 2020-09-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Поліпептид, що специфічно зв'язується з lrp5 і lrp6

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020178701A (ja) * 2015-12-04 2020-11-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 腫瘍細胞においてｗｎｔシグナル伝達に拮抗する二重パラトピックポリペプチド

Also Published As

Publication number Publication date
SI3383425T1 (sl) 2020-11-30
CL2018001384A1 (es) 2018-09-14
CN108289943A (zh) 2018-07-17
EP3383425B1 (en) 2020-07-15
US10597449B2 (en) 2020-03-24
AU2016363787B2 (en) 2023-02-02
MA43368B1 (fr) 2020-09-30
UA122079C2 (uk) 2020-09-10
AU2016363787A1 (en) 2018-05-17
PE20181515A1 (es) 2018-09-21
US20170174762A1 (en) 2017-06-22
CN108289943B (zh) 2023-06-20
JP2019506841A (ja) 2019-03-14
HUE051777T2 (hu) 2021-03-29
TW201731868A (zh) 2017-09-16
AR106949A1 (es) 2018-03-07
KR102802241B1 (ko) 2025-05-07
PH12018501155A1 (en) 2019-01-28
EP3383425A1 (en) 2018-10-10
SA518391728B1 (ar) 2022-03-28
HK1255725A1 (en) 2019-08-23
MA43368A (fr) 2018-10-10
MY200933A (en) 2024-01-24
PH12018501155B1 (en) 2024-06-28
CY1123454T1 (el) 2022-03-24
JP2020178701A (ja) 2020-11-05
EP3797790A1 (en) 2021-03-31
MA54648A (fr) 2021-11-10
BR112018010537A2 (pt) 2018-11-13
KR20180081825A (ko) 2018-07-17
US20200199222A1 (en) 2020-06-25
WO2017093478A1 (en) 2017-06-08
NZ742037A (en) 2025-07-25
CA3006235A1 (en) 2017-06-08
HRP20201528T1 (hr) 2020-12-11
CO2018005680A2 (es) 2018-06-12
EA201891331A1 (ru) 2018-12-28
DK3383425T3 (da) 2020-09-28
ES2821099T3 (es) 2021-04-23
TWI734719B (zh) 2021-08-01
LT3383425T (lt) 2020-10-12
US11952418B2 (en) 2024-04-09
RS60823B1 (sr) 2020-10-30
PT3383425T (pt) 2020-10-07
MX2018006760A (es) 2018-08-01
IL259119B (en) 2022-04-01
IL259119A (en) 2018-06-28
MX380414B (es) 2025-03-12
SG11201804510PA (en) 2018-06-28
PL3383425T3 (pl) 2021-01-11

Similar Documents

Publication Publication Date Title
JP6728355B2 (ja) 腫瘍細胞においてｗｎｔシグナル伝達に拮抗する二重パラトピックポリペプチド
US12285493B2 (en) Polypeptides antagonizing Wnt signaling in tumor cells
HK40040630A (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
HK1255725B (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
EA046752B1 (ru) Полипептиды, препятствующие передаче wnt сигналов в опухолевых клетках
EA040170B1 (ru) БИПАРАТОПНЫЕ ПОЛИПЕПТИДЫ-АНТАГОНИСТЫ ПЕРЕДАЧИ СИГНАЛА Wnt В ОПУХОЛЕВЫХ КЛЕТКАХ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200416

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200601

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200701

R150 Certificate of patent or registration of utility model

Ref document number: 6728355

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250